Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Evaluation of the pharmacokinetics and safety of AMG 986 tablet and capsule formulations in healthy adult subjects: a phase I, open-label, randomized study
The key regulatory milestones: FDA Breakthrough Therapy designation for MASH (September 2024) EMA PRIME designation for MASH (November 2023) China NMPA Breakthrough designation (June 2024) Phase 3 trials (SYNCHRONIZE-1 and SYNCHRONIZE-2) fully enrolled, results expected H1 of this year Estimated FDA filing: Late this year at the earliest Estimated FDA approval: Possibly next year, depending on Phase 3 results If Phase 3 results confirm Phase 2 findings, survodutide could reach the market within the next 12-24 months
Are Counter meals suitable for GLP-1 users
Small molecules like nicotine can move through skin, but larger ones usually cannot
Considerations to Weigh: Compounded vs
The regulatory team, manufacturing infrastructure, and commercial playbook are already in place
US$ 25.68
US$ 24.01
US$ 23.59
US$ 27.62
US$ 29.31
